Regulation of FGF2-induced proliferation by inhibitory GPCR in normal pituitary cells

Front Endocrinol (Lausanne). 2023 Jul 27:14:1183151. doi: 10.3389/fendo.2023.1183151. eCollection 2023.

Abstract

Introduction: Intracellular communication is essential for the maintenance of the anterior pituitary gland plasticity. The aim of this study was to evaluate whether GPCR-Gαi modulates basic fibroblast growth factor (FGF2)-induced proliferative activity in normal pituitary cell populations.

Methods: Anterior pituitary primary cell cultures from Wistar female rats were treated with FGF2 (10ng/mL) or somatostatin analog (SSTa, 100nM) alone or co-incubated with or without the inhibitors of GPCR-Gαi, pertussis toxin (PTX, 500nM), MEK inhibitor (U0126, 100µM) or PI3K inhibitor (LY 294002, 10 μM).

Results: FGF2 increased and SSTa decreased the lactotroph and somatotroph BrdU uptak2e (p<0.05) whereas the FGF2-induced S-phase entry was prevented by SSTa co-incubation in both cell types, with these effects being reverted by PTX, U0126 or LY294002 pre-incubation. The inhibition of lactotroph and somatotroph mitosis was associated with a downregulation of c-Jun expression, a decrease of phosphorylated (p) ERK and pAKT. Furthermore, SSTa was observed to inhibit the S-phase entry induced by FGF2, resulting in a further increase in the number of cells in the G1 phase and a concomitant reduction in the number of cells in the S phases (p< 0.05), effects related to a decrease of cyclin D1 expression and an increase in the expression of the cell cycle inhibitors p27 and p21.

Discussion: In summary, the GPCR-Gαi activated by SSTa blocked the pro-proliferative effect of FGF2 in normal pituitary cells via a MEK-dependent mechanism, which acts as a mediator of both anti and pro-mitogenic signals, that may regulate the principal effectors of the G1 to S-phase transition.

Keywords: FGF2; S-phase; SST analog; inhibitory GPCR; pituitary.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation
  • Female
  • Fibroblast Growth Factor 2* / pharmacology
  • Mitogen-Activated Protein Kinase Kinases
  • Phosphatidylinositol 3-Kinases / metabolism
  • Pituitary Gland* / cytology
  • Pituitary Gland* / drug effects
  • Rats
  • Rats, Wistar

Substances

  • Fibroblast Growth Factor 2
  • Mitogen-Activated Protein Kinase Kinases
  • Phosphatidylinositol 3-Kinases
  • U 0126

Grants and funding

This work was supported by the Agencia Nacional de Promoción Científica y Tecnológica, Fondo Nacional de Ciencia y Tecnología (ANPCyT-FONCYT-PICT 2014-2555), Ministerio de Ciencia y Tecnologia de la Ciudad de Cordoba (MINCyT 2018) and Secretaría de Ciencia y Tecnología de la Universidad Nacional de Córdoba (SECyT–UNC Res #/2018).